Bristol Myers Squibb appointed Cristian Massacesi, former chief medical officer at AstraZeneca and Alexion, as its new CMO effective August 1. Massacesi replaces Samit Hirawat who oversaw the launch of several key drugs including Reblozyl and Camzyos. Massacesi's experience in oncology drug development and regulatory approvals aligns with Bristol Myers' strategy as it faces patent expirations and competition for key products. The leadership change signals BMS's intent to sustain its pipeline and advance breakthrough medicines in oncology and other fields.